Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Polyol pathway links glucose metabolism to the aggressiveness of cancer cells.

Schwab A, Siddiqui A, Vazakidou ME, Napoli F, Böttcher M, Menchicchi B, Raza U, Saatci Ö, Krebs AM, Ferrazzi F, Rapa I, Dettmer-Wilde K, Waldner MJ, Ekici AB, Rasheed SAK, Mougiakakos D, Oefner PJ, Şahin Ö, Volante M, Greten FR, Brabletz T, Ceppi P.

Cancer Res. 2018 Jan 17. pii: canres.2834.2017. doi: 10.1158/0008-5472.CAN-17-2834. [Epub ahead of print]

PMID:
29343522
2.

Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss.

Lucas S, Omata Y, Hofmann J, Böttcher M, Iljazovic A, Sarter K, Albrecht O, Schulz O, Krishnacoumar B, Krönke G, Herrmann M, Mougiakakos D, Strowig T, Schett G, Zaiss MM.

Nat Commun. 2018 Jan 4;9(1):55. doi: 10.1038/s41467-017-02490-4.

3.

Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.

Steven A, Leisz S, Wickenhauser C, Schulz K, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2017 Oct 27;8(57):97439-97463. doi: 10.18632/oncotarget.22135. eCollection 2017 Nov 14.

4.

In mammalian skeletal muscle, phosphorylation of TOMM22 by protein kinase CSNK2/CK2 controls mitophagy.

Kravic B, Harbauer AB, Romanello V, Simeone L, Vögtle FN, Kaiser T, Straubinger M, Huraskin D, Böttcher M, Cerqua C, Martin ED, Poveda-Huertes D, Buttgereit A, Rabalski AJ, Heuss D, Rudolf R, Friedrich O, Litchfield D, Marber M, Salviati L, Mougiakakos D, Neuhuber W, Sandri M, Meisinger C, Hashemolhosseini S.

Autophagy. 2018 Feb 1:1-25. doi: 10.1080/15548627.2017.1403716. [Epub ahead of print]

PMID:
29165030
5.

PD-L1/PD-1: new kid on the "immune metabolic" block.

Qorraj M, Böttcher M, Mougiakakos D.

Oncotarget. 2017 Sep 5;8(43):73364-73365. doi: 10.18632/oncotarget.20639. eCollection 2017 Sep 26. No abstract available.

6.

A defined metabolic state in pre B cells governs B-cell development and is counterbalanced by Swiprosin-2/EFhd1.

Stein M, Dütting S, Mougiakakos D, Bösl M, Fritsch K, Reimer D, Urbanczyk S, Steinmetz T, Schuh W, Bozec A, Winkler TH, Jäck HM, Mielenz D.

Cell Death Differ. 2017 Jul;24(7):1239-1252. doi: 10.1038/cdd.2017.52. Epub 2017 May 19.

PMID:
28524857
7.

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.

Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, Brunton VG, Pilarsky C, Winkler TH, Brabletz S, Stemmler MP, Brabletz T.

Nat Cell Biol. 2017 May;19(5):518-529. doi: 10.1038/ncb3513. Epub 2017 Apr 17.

PMID:
28414315
8.

CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D.

Bruns H, Böttcher M, Qorraj M, Fabri M, Jitschin S, Dindorf J, Busch L, Jitschin R, Mackensen A, Mougiakakos D.

Leukemia. 2017 Apr;31(4):985-988. doi: 10.1038/leu.2016.378. Epub 2016 Dec 23. No abstract available.

PMID:
28008175
9.

Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Henrich FC, Singer K, Poller K, Bernhardt L, Strobl CD, Limm K, Ritter AP, Gottfried E, Völkl S, Jacobs B, Peter K, Mougiakakos D, Dettmer K, Oefner PJ, Bosserhoff AK, Kreutz MP, Aigner M, Mackensen A.

Oncoimmunology. 2016 Jun 10;5(8):e1184802. doi: 10.1080/2162402X.2016.1184802. eCollection 2016 Aug.

10.

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.

Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.

Leukemia. 2017 Feb;31(2):470-478. doi: 10.1038/leu.2016.214. Epub 2016 Aug 1.

PMID:
27479178
11.

Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B.

Oncotarget. 2016 Aug 9;7(32):52061-52084. doi: 10.18632/oncotarget.10474.

12.

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.

Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalén M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S, Wiklander OP, Nordin JZ, Skog J, Romain C, Koestler T, Hellgren-Johansson L, Schiller P, Joachimsson PO, Hägglund H, Mattsson M, Lehtiö J, Faridani OR, Sandberg R, Korsgren O, Krampera M, Weiss DJ, Grinnemo KH, Le Blanc K.

Stem Cells Transl Med. 2016 Jun;5(6):845. doi: 10.5966/sctm.2015-0021erratum. No abstract available.

13.

TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection.

Schleicher U, Paduch K, Debus A, Obermeyer S, König T, Kling JC, Ribechini E, Dudziak D, Mougiakakos D, Murray PJ, Ostuni R, Körner H, Bogdan C.

Cell Rep. 2016 May 3;15(5):1062-1075. doi: 10.1016/j.celrep.2016.04.001. Epub 2016 Apr 21.

14.

CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis.

Braun M, Qorraj M, Büttner M, Klein FA, Saul D, Aigner M, Huber W, Mackensen A, Jitschin R, Mougiakakos D.

Leukemia. 2016 Aug;30(8):1788-92. doi: 10.1038/leu.2016.58. Epub 2016 Mar 8. No abstract available.

PMID:
26952837
15.

Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.

Chevalier N, Mueller M, Mougiakakos D, Ihorst G, Marks R, Schmitt-Graeff A, Veelken H.

Leuk Lymphoma. 2016 Sep;57(9):2150-60. doi: 10.3109/10428194.2015.1135432. Epub 2016 Jan 12.

PMID:
26757600
16.

Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.

Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, Chmielewski M, Riet T, Abken H, Kiessling R.

J Immunol. 2016 Jan 15;196(2):759-66. doi: 10.4049/jimmunol.1401710. Epub 2015 Dec 16.

17.

Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation.

Böttcher M, Hofmann AD, Bruns H, Haibach M, Loschinski R, Saul D, Mackensen A, Le Blanc K, Jitschin R, Mougiakakos D.

Stem Cells. 2016 Feb;34(2):516-21. doi: 10.1002/stem.2234. Epub 2015 Nov 17.

18.

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.

Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalén M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S, Wiklander OP, Nordin JZ, Skog J, Romain C, Koestler T, Hellgren-Johansson L, Schiller P, Joachimsson PO, Hägglund H, Mattsson M, Lehtiö J, Faridani OR, Sandberg R, Korsgren O, Krampera M, Weiss DJ, Grinnemo KH, Le Blanc K.

Stem Cells Transl Med. 2015 Oct;4(10):1199-213. doi: 10.5966/sctm.2015-0021. Epub 2015 Aug 18. Erratum in: Stem Cells Transl Med. 2016 Jun;5(6):845.

19.

Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.

Ligtenberg MA, Çınar Ö, Holmdahl R, Mougiakakos D, Kiessling R.

PLoS One. 2015 Jun 15;10(6):e0129786. doi: 10.1371/journal.pone.0129786. eCollection 2015.

20.

Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.

Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M.

Mol Cancer. 2015 Jun 4;14:114. doi: 10.1186/s12943-015-0378-1.

21.

Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation.

von Bahr L, Blennow O, Alm J, Björklund A, Malmberg KJ, Mougiakakos D, Le Blanc A, Oefner PJ, Labopin M, Ljungman P, Le Blanc K.

Bone Marrow Transplant. 2015 Sep;50(9):1217-23. doi: 10.1038/bmt.2015.123. Epub 2015 Jun 1.

PMID:
26030049
22.

Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.

Leisz S, Schulz K, Erb S, Oefner P, Dettmer K, Mougiakakos D, Wang E, Marincola FM, Stehle F, Seliger B.

Oncotarget. 2015 May 10;6(13):11395-406.

23.

Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.

Bruns H, Büttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, Beier F, Pasemann S, Jitschin R, Hofmann AD, Neumann F, Daniel C, Maurberger A, Kempkes B, Amann K, Mackensen A, Gerbitz A.

Sci Transl Med. 2015 Apr 8;7(282):282ra47. doi: 10.1126/scitranslmed.aaa3230.

PMID:
25855493
24.

Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling.

Jitschin R, Braun M, Qorraj M, Saul D, Le Blanc K, Zenz T, Mougiakakos D.

Blood. 2015 May 28;125(22):3432-6. doi: 10.1182/blood-2014-10-607036. Epub 2015 Mar 16.

25.

Contact-dependent depletion of hydrogen peroxide by catalase is a novel mechanism of myeloid-derived suppressor cell induction operating in human hepatic stellate cells.

Resheq YJ, Li KK, Ward ST, Wilhelm A, Garg A, Curbishley SM, Blahova M, Zimmermann HW, Jitschin R, Mougiakakos D, Mackensen A, Weston CJ, Adams DH.

J Immunol. 2015 Mar 15;194(6):2578-86. doi: 10.4049/jimmunol.1401046. Epub 2015 Feb 9.

26.

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

Jitschin R, Braun M, Büttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause SW, Oefner PJ, Le Blanc K, Mackensen A, Mougiakakos D.

Blood. 2014 Jul 31;124(5):750-60. doi: 10.1182/blood-2013-12-546416. Epub 2014 May 21.

27.

Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia.

Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D.

Blood. 2014 Apr 24;123(17):2663-72. doi: 10.1182/blood-2013-10-532200. Epub 2014 Feb 19.

28.

Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany.

Aigner M, Bruns H, Gary R, Jitschin R, Kremer A, Mougiakakos D, Völkl S, Mackensen A, Gerbitz A.

Cancer Immunol Immunother. 2014 Feb;63(2):185-93. doi: 10.1007/s00262-013-1498-3. Epub 2013 Nov 5. No abstract available.

PMID:
24190547
29.

Myeloid-derived suppressor cells in allogeneic hematopoietic stem cell transplantation: A double-edged sword?

Le Blanc K, Jitschin R, Mougiakakos D.

Oncoimmunology. 2013 Jul 1;2(7):e25009. Epub 2013 May 16.

30.

Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.

Jitschin R, Mougiakakos D, Von Bahr L, Völkl S, Moll G, Ringden O, Kiessling R, Linder S, Le Blanc K.

Stem Cells. 2013 Aug;31(8):1715-25. doi: 10.1002/stem.1386.

31.

Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells.

Kiessling R, Okita R, Mougiakakos D, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kono K.

Oncoimmunology. 2012 Oct 1;1(7):1200-1201.

32.

Comparative expression profiling of distinct T cell subsets undergoing oxidative stress.

Lichtenfels R, Mougiakakos D, Johansson CC, Dressler SP, Recktenwald CV, Kiessling R, Seliger B.

PLoS One. 2012;7(7):e41345. doi: 10.1371/journal.pone.0041345. Epub 2012 Jul 20.

33.

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.

Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K.

Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215. Epub 2012 Jul 25.

PMID:
22828446
34.

Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells.

Mougiakakos D, Machaczka M, Jitschin R, Klimkowska M, Entesarian M, Bryceson YT, Henter JI, Sander B, Le Blanc K.

Stem Cells Dev. 2012 Nov 20;21(17):3147-51. doi: 10.1089/scd.2012.0214. Epub 2012 Jul 30.

PMID:
22738174
35.

Multipotent mesenchymal stromal cells and the innate immune system.

Le Blanc K, Mougiakakos D.

Nat Rev Immunol. 2012 Apr 25;12(5):383-96. doi: 10.1038/nri3209. Review.

PMID:
22531326
36.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

37.

High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Mougiakakos D, Okita R, Ando T, Dürr C, Gadiot J, Ichikawa J, Zeiser R, Blank C, Johansson CC, Kiessling R.

J Mol Med (Berl). 2012 Aug;90(8):935-44. doi: 10.1007/s00109-012-0857-4. Epub 2012 Jan 17.

PMID:
22249522
38.

Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses.

Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, Elgue G, Nilsson-Ekdahl K, Mougiakakos D, Lambris JD, Ringdén O, Le Blanc K, Nilsson B.

PLoS One. 2011;6(7):e21703. doi: 10.1371/journal.pone.0021703. Epub 2011 Jul 1.

39.

Camouflage and sabotage: tumor escape from the immune system.

Poschke I, Mougiakakos D, Kiessling R.

Cancer Immunol Immunother. 2011 Aug;60(8):1161-71. doi: 10.1007/s00262-011-1012-8. Epub 2011 Apr 6. Review.

PMID:
21626032
40.

Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?

Sundin M, D'arcy P, Johansson CC, Barrett AJ, Lönnies H, Sundberg B, Nava S, Kiessling R, Mougiakakos D, Le Blanc K.

J Immunother. 2011 May;34(4):336-42. doi: 10.1097/CJI.0b013e318217007c.

41.

Nuclear HER3 is associated with favorable overall survival in uveal melanoma.

Trocmé E, Mougiakakos D, Johansson CC, All-Eriksson C, Economou MA, Larsson O, Seregard S, Kiessling R, Lin Y.

Int J Cancer. 2012 Mar 1;130(5):1120-7. doi: 10.1002/ijc.26118. Epub 2011 Jun 18.

42.

The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells.

Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K.

Blood. 2011 May 5;117(18):4826-35. doi: 10.1182/blood-2010-12-324038. Epub 2011 Mar 9.

43.

Regulatory T cells in colorectal cancer: from biology to prognostic relevance.

Mougiakakos D.

Cancers (Basel). 2011 Mar 29;3(2):1708-31. doi: 10.3390/cancers3021708.

44.

DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.

Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, Ljungberg K.

Mol Ther. 2011 Mar;19(3):594-601. doi: 10.1038/mt.2010.268. Epub 2010 Dec 14.

45.

Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress.

Mougiakakos D, Johansson CC, Jitschin R, Böttcher M, Kiessling R.

Blood. 2011 Jan 20;117(3):857-61. doi: 10.1182/blood-2010-09-307041. Epub 2010 Oct 28.

46.

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R.

Int J Cancer. 2011 Jan 15;128(2):390-401. doi: 10.1002/ijc.25613. Epub 2010 Oct 13.

47.

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R.

Cancer Res. 2010 Jun 1;70(11):4335-45. doi: 10.1158/0008-5472.CAN-09-3767. Epub 2010 May 18.

48.

Regulatory T cells in cancer.

Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC.

Adv Cancer Res. 2010;107:57-117. doi: 10.1016/S0065-230X(10)07003-X. Review.

PMID:
20399961
49.

Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.

Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R.

Cancer. 2010 May 1;116(9):2224-33. doi: 10.1002/cncr.24999.

50.

Expression and prognostic significance of iNOS in uveal melanoma.

Johansson CC, Mougiakakos D, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R.

Int J Cancer. 2010 Jun 1;126(11):2682-9. doi: 10.1002/ijc.24984.

Supplemental Content

Loading ...
Support Center